Jongsuk Chung

1.2k total citations
14 papers, 138 citations indexed

About

Jongsuk Chung is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Jongsuk Chung has authored 14 papers receiving a total of 138 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Jongsuk Chung's work include Cancer Genomics and Diagnostics (8 papers), Genomics and Rare Diseases (4 papers) and Molecular Biology Techniques and Applications (4 papers). Jongsuk Chung is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Genomics and Rare Diseases (4 papers) and Molecular Biology Techniques and Applications (4 papers). Jongsuk Chung collaborates with scholars based in South Korea, Japan and United Kingdom. Jongsuk Chung's co-authors include Donghyun Park, Dae‐Soon Son, Woong‐Yang Park, Mi‐La Cho, Suk-Jung Choi, Kyoung‐Mee Kim, Hyo Jeong Jeon, Sun Shim Choi, Gyu Ha Ryu and Chung Lee and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Jongsuk Chung

14 papers receiving 135 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jongsuk Chung South Korea	7	71	55	45	23	21	14	138
Johanna Zerbib Israel	4	76 1.1×	58 1.1×	28 0.6×	12 0.5×	23 1.1×	5	135
Karolína Trachtová Czechia	7	133 1.9×	108 2.0×	29 0.6×	28 1.2×	11 0.5×	17	205
Wanxiangfu Tang China	7	133 1.9×	77 1.4×	51 1.1×	34 1.5×	19 0.9×	21	228
Daliah Tsoref Israel	6	66 0.9×	33 0.6×	59 1.3×	23 1.0×	41 2.0×	15	166
Anthoula Koliadi Sweden	7	66 0.9×	25 0.5×	70 1.6×	25 1.1×	20 1.0×	13	151
Athéna Sklias France	6	133 1.9×	73 1.3×	24 0.5×	18 0.8×	14 0.7×	6	171
Wolfgang Meinerz Germany	4	43 0.6×	68 1.2×	73 1.6×	11 0.5×	36 1.7×	7	143
María Ruiz-Miró Spain	7	116 1.6×	90 1.6×	26 0.6×	17 0.7×	7 0.3×	7	149
Joseph F. Boland United States	5	76 1.1×	27 0.5×	17 0.4×	9 0.4×	15 0.7×	8	120
David Huntsman Canada	2	66 0.9×	72 1.3×	57 1.3×	24 1.0×	23 1.1×	3	216

Countries citing papers authored by Jongsuk Chung

Since Specialization

Citations

This map shows the geographic impact of Jongsuk Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jongsuk Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jongsuk Chung more than expected).

Fields of papers citing papers by Jongsuk Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jongsuk Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jongsuk Chung. The network helps show where Jongsuk Chung may publish in the future.

Co-authorship network of co-authors of Jongsuk Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Jongsuk Chung. A scholar is included among the top collaborators of Jongsuk Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jongsuk Chung. Jongsuk Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Kim, Se Ik, Je‐Gun Joung, Yoo‐Na Kim, et al.. (2024). Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial. Gynecologic Oncology. 182. 7–14. 4 indexed citations

Kim, Yoo‐Na, Je‐Gun Joung, Eunhyang Park, et al.. (2023). Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045. International Journal of Cancer. 153(12). 2032–2044. 6 indexed citations

Shin, Seung‐Ho, Stephanie H. Kim, Hyeyeun Lim, et al.. (2022). Integrative analysis of plasma cell-free DNA fragmentation and methylation patterns for colorectal cancer detection.. Journal of Clinical Oncology. 40(16_suppl). e15022–e15022. 1 indexed citations

Park, Junsik, Eunhyang Park, Je‐Gun Joung, et al.. (2022). Abstract CT010: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer (KGOG 3046/TRU-D). Cancer Research. 82(12_Supplement). CT010–CT010. 4 indexed citations

Choi, Suk-Jung, Jongsuk Chung, Mi‐La Cho, Donghyun Park, & Sun Shim Choi. (2021). Analysis of changes in microbiome compositions related to the prognosis of colorectal cancer patients based on tissue-derived 16S rRNA sequences. Journal of Translational Medicine. 19(1). 485–485. 26 indexed citations

Chung, Jongsuk, et al.. (2021). Fast Healthcare Interoperability Resources (FHIR)–Based Quality Information Exchange for Clinical Next-Generation Sequencing Genomic Testing: Implementation Study. Journal of Medical Internet Research. 23(4). e26261–e26261. 5 indexed citations

Lee, Jung‐Yun, Jae‐Weon Kim, Byoung‐Gie Kim, et al.. (2021). KGOG 3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage epithelial ovarian cancer. Gynecologic Oncology. 162. S39–S40. 3 indexed citations

Hong, Tae Hee, Hongui Cha, Joonho Shim, et al.. (2020). Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. Journal for ImmunoTherapy of Cancer. 8(2). e001199–e001199. 10 indexed citations

Chung, Jongsuk, Chung Lee, Seung‐Ho Shin, et al.. (2019). Performance evaluation of commercial library construction kits for PCR-based targeted sequencing using a unique molecular identifier. BMC Genomics. 20(1). 216–216. 12 indexed citations

10.

Chung, Jongsuk, Sook‐Young Kim, Byung-Suk Kim, et al.. (2019). Benchmark Database for Process Optimization and Quality Control of Clinical Cancer Panel Sequencing. Biotechnology and Bioprocess Engineering. 24(5). 793–798. 1 indexed citations

11.

Lee, Chung, Joon Seol Bae, Gyu Ha Ryu, et al.. (2017). A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single-Nucleotide Variant Detection. Journal of Molecular Diagnostics. 19(5). 651–658. 15 indexed citations

12.

Lee, Hojun, Taeseob Lee, Donghyun Park, et al.. (2017). Performance evaluation method for read mapping tool in clinical panel sequencing. Genes & Genomics. 40(2). 189–197. 11 indexed citations

13.

Chung, Jongsuk, Dae‐Soon Son, Hyo Jeong Jeon, et al.. (2016). The minimal amount of starting DNA for Agilent’s hybrid capture-based targeted massively parallel sequencing. Scientific Reports. 6(1). 26732–26732. 34 indexed citations

14.

Son, Dae‐Soon, Donghyuk Lee, Kyusang Lee, et al.. (2014). Practical approach to determine sample size for building logistic prediction models using high-throughput data. Journal of Biomedical Informatics. 53. 355–362. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact